cis-1,3,5-Trimethyl-piperidin | 14446-76-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: cis-1,3,5-Trimethyl-piperidin
• 英文别名: cis-1,3,5-Trimethylpiperidine；(3R,5S)-1,3,5-trimethylpiperidine
• CAS: 14446-76-5
• 化学式: C₈H₁₇N
• 分子量: 127.23
• InChiKey: IGJDIGJIINCEDE-OCAPTIKFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• DIAMINE DERIVATIVE
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1847530A1

  公开（公告）日：2007-10-24

  The present invention provides a diamine derivative or the like represented by the general formula (I): wherein Q represents an oxygen atom or the like, RG represents a hydrogen atom or the like, RI represents (wherein p and r may be the same or different, and each represents 0 or the like, RA represents a hydrogen atom or the like, and RB and Rc may be the same or different, and each represents a hydrogen atom or the like), RH represents a hydrogen atom or the like, and RJ represents: (wherein q and s may be the same or different, and each represents 0 or the like, RD represents a hydrogen atom or the like, and RE and RF may be the same or different, and each represents a hydrogen atom or the like) or the like}, etc.

  本发明提供了一种二胺衍生物等，由通式(I)表示：其中Q表示氧原子等，RG表示氢原子等，RI表示（其中p和r可以相同或不同，各自表示0或等，RA表示氢原子等，RB和RC可以相同或不同，各自表示氢原子等），RH表示氢原子等，RJ表示：（其中q和s可以相同或不同，各自表示0或等，RD表示氢原子等，RE和RF可以相同或不同，各自表示氢原子等）等}，等等。
• [EN] THIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND THEIR USE AS TYK2 KINASE INHIBITORS<br/>[FR] COMPOSÉS DE THIAZOLOPYRIDINE, COMPOSITIONS ET LEUR UTILISATION COMME INHIBITEURS DE LA KINASE TYK2
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015091584A1

  公开（公告）日：2015-06-25

  Provided are thiazolopyridine compounds that are inhibitors of TYK2 kinase, compositions containing these compounds and methods for treating diseases mediated by TYK2 kinase. In particular, provided are compounds of Formula (I), (II) or (III), stereoisomers, tautomers, solvates, prodrugs or pharmaceutically acceptable salts thereof, where X, R0, R1, R2, R3, R4 and R5 are defined herein, pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, for example, for treating a disease or condition mediated by TYK2 kinase in a patient.

  提供了一些噻唑吡啶化合物，这些化合物是TYK2激酶的抑制剂，包含这些化合物的组合物以及治疗由TYK2激酶介导的疾病的方法。具体来说，提供了符合Formula (I)、(II)或(III)的化合物，其立体异构体、互变异构体、溶剂合物、前药或其药用可接受的盐，其中X、R0、R1、R2、R3、R4和R5在此有定义，包括该化合物和药用可接受的载体、辅料或溶剂的药物组合物，使用该化合物或组合物进行治疗的方法，例如，用于治疗患有TYK2激酶介导的疾病或症状的患者。
• Pyrrolopyridine kinase inhibiting compounds
  申请人：Dong Han-Qing

  公开号：US20070129364A1

  公开（公告）日：2007-06-07

  Compounds represented by Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least one of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3β, EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, IGF-1R, Ron, Met, and KDR kinases in animals, including humans, for the treatment and/or prevention of various diseases and conditions such as cancer.

  由式（I）表示的化合物或其立体异构体或其药用可接受的盐，是对动物中至少一种Abl、Aurora-A、Blk、c-Raf、cSRC、Src、PRK2、FGFR3、Flt3、Lck、Mek1、PDK-1、GSK3β、EGFR、p70S6K、BMX、SGK、CaMKII、Tie-2、IGF-1R、Ron、Met和KDR激酶的抑制剂，包括人类，用于治疗和/或预防癌症等各种疾病和病况。
• DEUTERATED BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF
  申请人：ENANTA PHARMACEUTICALS, INC.

  公开号：US20170240585A1

  公开（公告）日：2017-08-24

  The present invention provides compounds of Formula (I) or Formula (II): pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.

  本发明提供了化合物的化学式(I)或化学式(II)：包括这些化合物的药物组合物以及使用这些化合物来治疗或预防由FXR和/或TGR5介导的疾病或紊乱的方法。
• [EN] INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] FORMULATIONS INHALÉES D'INHIBITEURS DE PGDH ET LEURS PROCÉDÉS D'UTILISATION
  申请人：EPIRIUM BIO INC

  公开号：WO2022082009A1

  公开（公告）日：2022-04-21

  Disclosed herein are compounds that can inhibit 15-hydroxyprostaglandin dehydrogenase. Such compounds may be administered to subjects that may benefit from modulation of prostaglandin levels. In some embodiments, the compounds disclosed herein are formulated for delivery via inhalation. In some embodiments, the compounds disclosed herein are useful for the treatment of respiratory disorders.

  本文所披露的化合物可以抑制15-羟基前列腺素脱氢酶。这样的化合物可以被用于给予需要调节前列腺素水平的受试者。在某些实施例中，本文所披露的化合物是通过吸入途径给予的。在某些实施例中，本文所披露的化合物对于治疗呼吸系统疾病是有用的。

表征谱图